eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2021
vol. 7
 
Share:
Share:
abstract:
Original paper

Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development

Eman Saad Nassar
1
,
Yomna Abdelrazek Elkalbashawy
1
,
Ahmed Kamal
2
,
Nermine Hossam Eldin Zakaria
1

1.
Clinical and Chemical Pathology, Alexandria University, Egypt
2.
Hepatology Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Egypt
Clin Exp HEPATOL 2021; 7, 1: 74-78
Online publish date: 2021/03/15
View full text Get citation
 
PlumX metrics:
Aim of the study
Ultrasound surveillance for hepatocellular carcinoma (HCC) among cirrhotic patients is the currently used modality but it is operator dependent. Combining a tumor marker with ultrasound may improve sensitivity for early HCC detection. Our aim was to assess the galectin-3 level among HCC and cirrhotic patients on top of chronic hepatitis C to evaluate its possible role as a tumor marker for HCC surveillance among cirrhotic patients.

Material and methods
The study was conducted on 160 subjects. They were grouped as follows: group 1: 40 patients with HCC secondary to liver cirrhosis on top of chronic hepatitis C; group 2: 40 patients with cirrhosis secondary to chronic hepatitis C; group 3: 40 patients with chronic hepatitis C without advanced fibrosis; group 4: 40 healthy controls. Serum galectin-3 levels were determined in all subjects using ELISA.

Results
Serum galectin-3 level was significantly higher in HCC patients than in those with chronic hepatitis C (p < 0.001). Also it was significantly higher among cirrhotic patients than in patients with chronic hepatitis C (p < 0.001). But on comparing HCC patients with cirrhotic patients, serum galectin-3 levels were not significantly different (p = 0.926).

Conclusions
Galectin-3 levels cannot be used as an additional method for surveillance of HCC among cirrhotic patients.

keywords:

antiviral agents, liver cirrhosis, neoplasm recurrence

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.